To include your compound in the COVID-19 Resource Center, submit it here.

FDA posts boceprevir documents

FDA reviewers agreed with Merck & Co. Inc. (NYSE:MRK) that boceprevir is effective in treating HCV but questioned its safety in briefing

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE